Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by jfm1330on Aug 11, 2023 12:03pm
175 Views
Post# 35584004

RE:Novo Nordisk buys Inversago Pharma

RE:Novo Nordisk buys Inversago PharmaIt's making headlines here in  La Presse newspaper. As the article states, Inversago is the third Quebec's biotech bought for over a billion US in the last two years. They call the Inversago deal another homerun. Use Google traslate to read it in english. At the same time Thera's market cap is 40 M$ US.

The only optimism you can get out of these stories of buyouts, is that it's possible to turn things around. Thera did it in 2018, but it was a mirage, from a peak of 54 $ CAN per share to now 2 $ and Levesque was supposed to be such an upgrade at CEO...

https://www.lapresse.ca/affaires/chroniques/2023-08-11/un-autre-coup-de-circuit-par-une-biotech-quebecoise.php

jfm1330 wrote: You want to depress a little more about Thera ? Today a news came out that Novo Nordisk was buying Invesago Pharma, a drug development company based in Montreal. The founder of this company is Francois Ravenelle. He started it after he left Thera in the John Huss era. He was not even a V-P at Thera, just a director or something like that. So in about 10 years this bright guy was able to build a company that is now acquired by a big pharma for up to 1.075 billions US. This guy should have been V-P of pharmaceutical development at Thera, then the CEO.


<< Previous
Bullboard Posts
Next >>